Compugen Ltd
NASDAQ:CGEN
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.53
2.95
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CGEN stock under the Base Case scenario is 1.118 USD. Compared to the current market price of 1.759 USD, Compugen Ltd is Overvalued by 36%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Compugen Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CGEN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Compugen Ltd
Balance Sheet Decomposition
Compugen Ltd
Current Assets | 102.1m |
Cash & Short-Term Investments | 92m |
Receivables | 9.8m |
Other Current Assets | 333k |
Non-Current Assets | 8m |
Long-Term Investments | 3m |
PP&E | 4.1m |
Other Non-Current Assets | 922k |
Current Liabilities | 24.8m |
Accounts Payable | 4.9m |
Accrued Liabilities | 8.7m |
Other Current Liabilities | 11.3m |
Non-Current Liabilities | 27.1m |
Other Non-Current Liabilities | 27.1m |
Earnings Waterfall
Compugen Ltd
Revenue
|
42.7m
USD
|
Cost of Revenue
|
-5.7m
USD
|
Gross Profit
|
37.1m
USD
|
Operating Expenses
|
-41.6m
USD
|
Operating Income
|
-4.5m
USD
|
Other Expenses
|
-5m
USD
|
Net Income
|
-9.5m
USD
|
Free Cash Flow Analysis
Compugen Ltd
USD | |
Free Cash Flow | USD |
Compugen reported significant financial improvement with cash reserves rising to $92.3 million, up from $51.1 million at the end of 2023, and no debt. The company generated $6.7 million in Q2 2024, reflecting milestones from partnerships. Operational expenses were controlled, reducing net loss to $2.1 million compared to $9.3 million in 2023. Upcoming milestones include data presentations and a new Phase I trial, indicating steady progress in their oncology pipeline, especially in ovarian cancer and lung cancer collaborations with AstraZeneca. The company remains dedicated to advancing its innovative drug discovery platform, aiming to provide value to shareholders and meet critical medical needs.
What is Earnings Call?
CGEN Profitability Score
Profitability Due Diligence
Compugen Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Compugen Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
CGEN Solvency Score
Solvency Due Diligence
Compugen Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Compugen Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CGEN Price Targets Summary
Compugen Ltd
According to Wall Street analysts, the average 1-year price target for CGEN is 5.1 USD with a low forecast of 4.04 USD and a high forecast of 7.35 USD.
Dividends
Current shareholder yield for CGEN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Contact
IPO
Employees
Officers
The intrinsic value of one CGEN stock under the Base Case scenario is 1.118 USD.
Compared to the current market price of 1.759 USD, Compugen Ltd is Overvalued by 36%.